Amyotrophic Lateral Sclerosis

Phase II extension trial of CNM-Au8 in ALS 1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
The pipeline of late-stage therapeutic options for patients with ALS 1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
An overview of the developments in ALS research 1:15
An overview of the developments in ALS research
Matthew Kiernan • 4 Apr 2022
Important developments in understanding the mechanisms of ALS 1:47
Important developments in understanding the mechanisms of ALS
Matthew Kiernan • 4 Apr 2022
Personalizing therapy: the future of ALS treatment 1:48
Personalizing therapy: the future of ALS treatment
Nigel Leigh • 17 Mar 2022
Developing biomarker panels for ALS diagnosis 2:53
Developing biomarker panels for ALS diagnosis
Nigel Leigh • 17 Mar 2022
Changing our approach to ALS clinical trial design 3:44
Changing our approach to ALS clinical trial design
Nigel Leigh • 17 Mar 2022
MIROCALS: low-dosage IL-2 for the treatment of ALS 2:13
MIROCALS: low-dosage IL-2 for the treatment of ALS
Nigel Leigh • 17 Mar 2022
Assessing the role of measuring plasma neurofilament light levels in ALS 1:58
Assessing the role of measuring plasma neurofilament light levels in ALS
Nigel Leigh • 17 Mar 2022
AMD3100 in animal models of ALS and MS 1:11
AMD3100 in animal models of ALS and MS
Beka Solomon • 17 Mar 2022
Correlation between synaptic density and cognitive issues in ALS 6:28
Correlation between synaptic density and cognitive issues in ALS
Anna Sanchez Avila • 8 Mar 2022
How can the gut microbiome modulate the peripheral and brain immune systems? 4:45
How can the gut microbiome modulate the peripheral and brain immune systems?
Giulio Pasinetti • 18 Mar 2022
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS 2:44
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS
Matthew Kiernan • 4 Apr 2022
Ex vivo gene therapy for neurodegenerative diseases 2:20
Ex vivo gene therapy for neurodegenerative diseases
Clive Svendsen • 15 Mar 2022
Unanswered questions in ALS research 1:44
Unanswered questions in ALS research
Clive Svendsen • 15 Mar 2022
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
The content of VJNeurology is intended for healthcare professionals